Chemours Co SEC Filings

Courtney Mather, a director of Chemours Co (CC), reported acquisition of deferred stock units tied to common shares on 09/30/2025. The Form 4 shows 1,657 deferred stock units were acquired at a reported unit value of $15.84 each. Each deferred stock unit is the economic equivalent of one share of common stock and becomes payable after the director leaves board service. After the reported transaction the filing indicates the reporting person beneficially owns 3,960.9731 shares in a direct ownership form.

Gerardo Familiar Calderon, an officer at The Chemours Company (CC), reported a transaction dated 09/01/2025 in which 1,294 common shares were withheld to satisfy tax obligations on vesting restricted stock units and dividend equivalent units; the withholding was executed at a price of $15.40 per share and no shares were sold. The filing shows 33,949.9429 shares beneficially owned following the transaction; that total was reduced to correct an inadvertent over-reporting in a prior Form 4 filed August 5, 2025. The Form 4 was executed on 09/03/2025 by an attorney-in-fact.

The Chemours Company (CC) reporting person Will David, identified as the company's Chief Accounting Officer, reported a routine tax-withholding transaction tied to vested restricted stock units and dividend equivalent units. On 08/12/2025 2,374 shares were withheld at a price of $12.42 to satisfy tax obligations; no shares were sold and the transaction is exempt under Rule 16b-3. After the withholding, Mr. David beneficially owns 25,189.8011 shares (direct ownership). The filing includes a Power of Attorney as Exhibit 24 and was signed by an attorney-in-fact on 08/14/2025.

Denise Dignam, President & CEO and director of The Chemours Company (CC), purchased common stock on 08/08/2025. The Form 4 shows a purchase of 4,068 shares at a price of $12.06 per share, bringing her total reported beneficial ownership to 191,546.1549 shares. The filing notes the reported total includes directly owned shares, restricted stock units and dividend equivalent units.

The disclosure is a standard Section 16 insider report of a non-derivative acquisition and was submitted via Form 4. No options, conversions or derivative transactions are reported on this filing.

The Chemours Company reported an insider transaction by Shane Hostetter, its Chief Financial Officer. The filing shows 3,021 common shares were withheld to satisfy tax obligations on vesting restricted stock units and dividend equivalent units. The report indicates these withholding transactions were exempt under Rule 16b-3 and that no shares were sold in connection with the withholding.

The filing lists a per-share price of $12 for the withheld shares and shows total beneficial ownership following the transaction of 57,115.1539 shares, which the filer states includes directly owned shares, restricted stock units and dividend equivalent units.

The Schedule 13G/A for The Chemours Company shows Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander reported aggregate beneficial ownership of 7,576,095 shares of Chemours common stock, equal to 5.1% of the class. The filing specifies shared voting power of 7,443,038 and shared dispositive power of 7,576,095, and reports sole voting and dispositive powers as 0.

The filing states the reporting persons "ceased to be beneficial owners of more than 5% of the outstanding Common Stock as of July 1, 2025." The amendment is signed August 7, 2025, and includes a Joint Filing Agreement as Exhibit I. No purchase prices, transaction dates, or intent to influence control are disclosed in the document.